dacarbazine and iniparib

dacarbazine has been researched along with iniparib in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Donawho, CK; Ellis, PA; Harlan, JE; Iyer, R; Johnson, EF; Ladror, US; Liu, X; Maag, DX; Palma, JP; Patterson, MJ; Penning, TD; Ready, DB; Shi, Y; Shoemaker, AR; Solomon, LR; Soni, NB; Surber, BW; Xu, AJ	1
Blakeley, JO; Chi, AS; Desideri, S; Emmons, G; Garcia Ribas, I; Grossman, SA; Mikkelsen, T; Nabors, LB; Peereboom, D; Rosenfeld, MR; Supko, JG; Ye, X	1

Trials

1 trial(s) available for dacarbazine and iniparib

Article	Year
Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas. Journal of neuro-oncology, 2015, Volume: 125, Issue:1 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Treatment Outcome	2015

Article

Year

Phase I study of iniparib concurrent with monthly or continuous temozolomide dosing schedules in patients with newly diagnosed malignant gliomas.

Journal of neuro-oncology, 2015, Volume: 125, Issue:1

Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Poly(ADP-ribose) Polymerase Inhibitors; Temozolomide; Treatment Outcome

2015

Other Studies

1 other study(ies) available for dacarbazine and iniparib

Article	Year
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2 Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; BRCA2 Protein; Cell Line, Tumor; Cysteine; Dacarbazine; DNA Repair; Drug Synergism; Female; Humans; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms, Experimental; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays	2012

Article

Year

Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jan-15, Volume: 18, Issue:2

Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; BRCA2 Protein; Cell Line, Tumor; Cysteine; Dacarbazine; DNA Repair; Drug Synergism; Female; Humans; Mice; Mice, Inbred C57BL; Mice, SCID; Neoplasms, Experimental; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Temozolomide; Xenograft Model Antitumor Assays

2012